Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Finance
  • Published:

Navigating biotechnology's new fiscal opportunities

Nature Biotechnology volume 16, pages 51–53 (1998)Cite this article

Abstract

Bioentrepreneurs who fashion strategies designed to meet the changing needs of the pharmaceutical industry and the institutional investment community are likely to find deep pockets for funding.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2: The cost of inadequately treated diseases in the United States is over $450 billion per year.

Author information

Authors and Affiliations

  1. managing director of Hambrecht & Quist LLC, 230 Park Avenue, New York, 10169, NY

    Dennis J. Purcell

Authors
  1. Dennis J. Purcell
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Purcell, D. Navigating biotechnology's new fiscal opportunities. Nat Biotechnol 16 (Suppl 1), 51–53 (1998). https://doi.org/10.1038/5423

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/5423

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing